Use of Remote Imagery to Analyse Changes in Morphology and Longitudinal Large Wood Distribution in the Blanco River After the 2008 Chaiten Volcanic Eruption, Southern Chile

The 2008 Chaitén volcanic eruption generated significant changes in the channel morphology and large wood (LW) abundance along the fluvial corridor of the Blanco River, southern Chile. Comparisons of remote sensing images from the pre-eruption (year 2005) and post-eruption (years 2009 and 2012) conditions showed that in a 10.2km long study segment the Blanco River widened 3.5 times from 2005 to 2009, and that the maximum enlargement was nine times the original width. Changes in channel width were lower between the years 2012 and 2009. The sinuosity and braiding indexes also changed between 2005 and 2009. After the eruption the channel sinuosity was higher and specific river reaches developed a braided pattern, but by 2012 the channel was recovering pre-eruption characteristics. Huge quantities of LW were introduced to the study segment; individual LW per km of channel length were 1.6 and 74.3 in 2005 and 2009, respectively, and more than 30 log jams km-1 were observed in the year 2009. Between 2009 and 2012 the quantity of LW was very similar. Statistically significant relationships were found between the number of log jams and channel sinuosity and between the number of pieces of large wood with sinuosity and channel width. Wood was highly dynamic between 2009 and 2012: 78% of individual pieces and 48% of log jams identified in the 2009 image had moved by 2012. Finally the supervised classification of imagery associated with ArcMap tools was tested to identify large woo

Diagnóstico ultra-sonográfico do momento ovulatório em búfalas (Bubalus bubalis) inseminadas no estro espontâneo e induzido Ultrasonographical diagnosis of ovulation in buffaloes (Bubalus Bubalis) inseminated in spontaneous and induced oestrus

O objetivo deste experimento foi determinar o intervalo entre o início do estro induzido ou espontâneo e a ovulação em fêmeas bubalinas (Bubalus bubalis) com o auxílio da ultra-sonografia, o que permitirá a determinação de um horário mais apropriado para a I.A. pré-fixada. Nos meses de março a junho, outono no sul do Brasil (época reprodutiva dos bubalinos), 132 fêmeas adultas ciclando foram divididas em 3 grupos experimentais: Grupo A - 53 fêmeas foram tratadas com implante subcutâneo de Norgestomet ou espiral intravaginal contendo progesterona. Na retirada dos dispositivos, foi aplicado 250mg de cloprostenol pela via intra-submucosa vulvar (i.s.m.v.), Grupo B - 48 búfalas foram tratadas com dupla aplicação de 250mg de cloprostenol pela via i.s.m.v. com intervalo de 11 dias e Grupo C - 31 búfalas foram consideradas testemunhas, sem tratamento. Todas as búfalas foram inseminadas no momento da observação do maior diâmetro do folículo pré-ovulatório, detectado por ultra-sonografia, durante o estro. Após o diagnóstico de prenhez, constatou-se, nos três tratamentos, que houve diferença significativa entre as búfalas prenhes e vazias no período compreendido entre o início do estro até o momento da ovulação e no período entre a I.A.e a ovulação. Os índices de prenhez foram de 41,5%, 52,1% e 54,8% nos grupos A, B e C, respectivamente. A variação no intervalo estro-ovulação nas búfalas é uma barreira para a obtenção de taxas de prenhez por I.A. pré-fixada comparáveis à monta natural, tanto no estro induzido através de progesterona e prostaglandina F2 alfa como no estro espontâneo.<br>The aim of this experiment was to determine the interval between the beginning of the spontaneous or induced oestrus and the ovulation in females buffaloes using ultrasonography. This will be useful in the determination of the most proper moment for the pre-fixed artificial insemination. In the reproductive season, autumn in the South of Brazil (march-june), 132 clicling females were divided in 3 groups: Group A: 53 females were treated with auricular subcutaneous implant of norgestomet or intravaginal device of progesterone. In the moment that the devices were removed, 250mg of cloprostenol were applied for intravulvar submucosis (ivsm). Group B: 48 buffaloes females were treated twice with 250mg of cloprostenol for ivsm with interval of 11 days. Group C: 31 buffaloes females remained without any treatment (control group). All of them were inseminated in the moment that was observed the biggest diameter of pre-ovulatory follicle determinated by ultrasonography. In the 3 groups, there was significative difference between pregnant and non-pregnant females in the oestrus-ovulation interval and in the A.I.-ovulation interval. The pregnancy rates were 41.5%, 52.1% and 54.8% in the groups A, B amd C, respectively. The variation in the oestrus-ovulation in buffaloes is the major obstacle to achieve high pregnancy rates using pre-fixed artificial insemination in spontaneous and induced oestrus

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)